Iambic Therapeutics (IAM) Stock Price, News & Analysis

Company Overview

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design.

The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

Key Stats

• Today's Range: $12.68 to $15.06
• 50-Day Range: N/A
• 52-Week Range: $9.60 to $25.00
• Volume: 277,981 shs
• Average Volume: 757,415 shs
• Market Capitalization: $620.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.25
• Consensus Rating: Moderate Buy

Iambic Therapeutics Stock Analysis - MarketRank™

Iambic Therapeutics scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Iambic Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Iambic Therapeutics has a consensus price target of $27.25, representing about 108.0% upside from its current price of $13.10.

Amount of Analyst Coverage

Iambic Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Iambic Therapeutics are expected to decrease in the coming year, from ($1.83) to ($2.83) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.24% of the float of Iambic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iambic Therapeutics has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iambic Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iambic Therapeutics does not currently pay a dividend.

Dividend Growth

Iambic Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.41

News Sentiment

Iambic Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Iambic Therapeutics this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for IAM on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Iambic Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $11,500,000.00 in company stock, which represents 1.8520% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Iambic Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,500,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

22.90% of the stock of Iambic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Iambic Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IAM
• CIK: 1997038
• Web: www.iambic.ai
• Phone: (626) 592-2520
• Fax: N/A
• Employees: 171
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Iambic Therapeutics: $27.25
• High Price Target: $35.00
• Low Price Target: $22.00
• Potential Upside/Downside: +108.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 47,400,000
• Free Float: 36,546,000
• Market Cap: $620.94 million
• Optionable: N/A
• Beta: N/A